$CORT (-6,13 %)

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat serious endocrinologic, oncologic, metabolic and neurologic diseases by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company's pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, has met its primary endpoint of improved progression-free survival as determined by a blinded, independent pivotal review (PFS-BICR).

In the ROSELLA study, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy showed a 30 percent reduced risk of disease progression compared to patients receiving nab-paclitaxel alone (hazard ratio: 0.70; p-value: 0.008). Their median PFS-BICR was 6.5 months compared to 5.5 months in patients receiving nab-paclitaxel alone. In an interim assessment of overall survival (OS), patients treated with relacorilant plus nab-paclitaxel showed a significant improvement in OS with a median OS of 16.0 months compared to 11.5 months in patients receiving nab-paclitaxel alone (hazard ratio: 0.69; p-value: 0.012). Relacorilant was well tolerated and no new safety signals were observed. As in the company's Phase 2 study, safety and tolerability were comparable in both groups.

https://www.wallstreet-online.de/nachricht/19170527-primary-endpoint-met-corcept-s-pivotal-phase-3-rosella-trial-of-relacorilant-patients-with-platinum-resistant-ovarian-cancer

$CORT (-6,13 %)

Sales of USD 675.0 million in 2024, an increase of 40 percent compared to 2023

Sales forecast for 2025: USD 900 - 950 million

Net profit of USD 141.2 million in 2024, an increase of 33% compared to 2023

Cash and investments of USD 603.2 million as at December 31, 2024

https://www.businesswire.com/news/home/20250226825813/en/Corcept-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2024-Audited-Financial-Results-and-Provides-Corporate-Update

$CORT (-6,13 %)

On Tuesday, HC Wainwright raised its price target on shares of Corcept Therapeutics (NASDAQ: CORT ) to $115 from a previous $80, but maintained a Buy rating on the stock. The company's analyst cited the potential approval of Corcept's Relacorilant, a selective cortisol modulator, as a key factor for the company's future sales growth. The stock has already shown a remarkable performance, with a return of 193.52% over the past year, and is currently trading near its 52-week high of $71.29. According to InvestingPro's analysis, the company remains financially strong with a rating of 3.43 out of 5.

Corcept Therapeutics submitted a New Drug Application (NDA) to the FDA for Relacorilant for the treatment of hypercortisolism on December 30, 2024. The analyst expects the drug to receive FDA approval at the end of 2025 after a standard review period of approximately 10 months and to be launched in the first quarter of 2026. The company's strong fundamentals are reflected in its impressive gross profit margin of 98.44% and its sales growth of 39.67% over the last twelve months.

The increased price target reflects a new 90% probability for the drug's launch, a significant increase from the previous estimate of 48.5%. The analyst forecasts that if Relacorilant is successfully launched, revenues from the treatment of Cushing's syndrome could rise to nearly $824 million by 2030, up from an estimated $175 million in 2026.

In addition, the analyst pointed out that if Relacorilant is also used to treat patients with difficult-to-control diabetes, this could lead to significant growth beyond current revenue projections. This optimistic outlook underpins the company's decision to maintain a Buy rating and raise the 12-month price target for Corcept Therapeutics.

https://traderfox.de/aktien/corcept-therapeutics-inc-529882/

https://www.investing.com/news/analyst-ratings/hc-wainwright-lifts-corcept-stock-target-to-115-on-drug-outlook-93CH-3861488

the share should soon leave the base at the all-time high! $CORT (-6,13 %)

Clarification of proprietary positions: TraderFox editors are currently holding these shares from the article and @Tenbagger2024 .

Corcept Therapeutics focuses on the development of drugs that regulate cortisol levels. With Korlym, the company has a drug on the market that has been generating strong sales growth for years and is used to treat Cushing's syndrome. Cortisol is also known as the stress hormone, but excessive levels can lead to a range of disorders and diseases. The company has been profitable since 2016, with sales expected to increase by 40 to 45% to 700 million by the end of the 2024 financial year. For 2025, the consensus expects sales growth of only 17% to USD 801m and that seems very low to me, especially as management recently said that screening for Cushing's syndrome is becoming more common and the number of patients receiving treatment is increasing.

Interestingly, the company has a successor product to Korlym in the pipeline, Relacorilant, which could soon be approved. Corcept submitted its application for approval to the FDA on December 30, 2024. If approved, Relacorilant could help Corcept achieve its ambitious sales target of USD 3 billion by 2029, which would correspond to a more than four-fold increase in sales as of today.

I continue to find the Corcept story, which I presented in Tenbagger back in 2021, extremely exciting and I also like the chart. The share is in an upward trend and has formed a base at its all-time high, which could be broken to the upside in the near future (CORT).

https://aktien-mag.de/nachrichten/chart-tweets/die-behandlungszahlen-fur-das-cushing-syndrom-steigen-wodurch-corcept-therapeutics-mehr-aufmerksamkeit-erhalt-die-aktie-durfte-zeitnah-die-base-am-allzeithoch-verlassen/p-134999

Hello everyone, with Donald Trump and Elon Musk in office, I'm expecting volatile times ahead. I have therefore carried out a check on my portfolio to determine how solid my foundation (core) still is.

The following criteria were used for the check

Quality check

The quality check examines shares for the quality of the business model and the stability of the balance sheet

Enduring qualities

The long-term indicator checks whether share prices are constantly rising.

Outperformer check

Every investor is confronted with the question of whether to invest money passively in ETFs or in individual shares. A share should rise by more than 10% per year for an investment to be worthwhile.

KUV monster

When companies are hyped and everyone knows about the quality of a company, the return potential is usually low. The top 5% of the most highly valued shares according to the KUV criterion are problematic.

The following companies from my portfolio stood out in this regard

buy and leave.

Alphabet $GOOG (-3,48 %) Modine Manuf. $MOD (-14,01 %) Chipotle $CMG (-3,7 %)

Microsoft $MSFT (-2,62 %) Copart $CPRT (-3,09 %) Vertex $VRTX (-1,57 %)

Constellation Software $CSU (-4,19 %) Man and machine $MUM (-0,84 %)

Corcept Therap. $CORT (-6,13 %) Tetra Tech $TTI (-14,11 %) TransDigm Group $TDG (+0 %)

IES Holding $IES ASML $ASML (-7,33 %)

Share price target for Corcept Therapeutics raised, buy recommendation based on Cushing's franchise growth. $CORT (-6,13 %)

On Friday, HC Wainwright maintained its Buy rating on shares of Corcept Therapeutics (NASDAQ: CORT ) and raised its price target significantly from $45.00 to $80.00. The firm's decision reflects a positive outlook for the company's Cushing's syndrome treatment offering, including its flagship product Korlym.

The analyst at HC Wainwright pointed to the continued growth of Korlym sales in recent quarters, noting that the product appears to have been unaffected by generic competition from Teva Pharmaceuticals. The company's revised financial model now projects Korlym sales to reach nearly $531 million by 2030, a significant increase from the previously estimated $338 million for the same period

In addition to Korlym's strong performance, the analyst's optimism is also bolstered by expectations around Corcept's pipeline drug Relacorilant. The company is expected to submit a New Drug Application (NDA) by the end of 2024 and is expected to launch in the first quarter of 2026.

Assuming the drug is approved, HC Wainwright estimates the price of Relacorilant to be almost USD 378,000 per patient per year and forecasts that risk-adjusted revenues will start at USD 174 million in 2026 and eventually rise to USD 691 million by 2030.

The significant increase in the price target to $80 reflects the updated sales projections and the company's confidence in the future success of Corcept's Cushing's syndrome treatments. The analyst's comments and revised price target indicate the company's strong belief in capitalizing on the Cushing's syndrome market with its current and future product offerings.

In other recent news, Corcept Therapeutics has attracted significant attention due to its impressive financial performance and promising clinical developments. The company's second quarter revenues increased 39% year-over-year to $163.8 million, and net income reached $35.5 million. Following these strong results, Corcept's management has adjusted its revenue guidance for 2024 and now expects USD 640 to 670 million.

Analyst firms Truist Securities, Canaccord Genuity and Piper Sandler have maintained their positive ratings on Corcept shares, with Truist Securities raising its price target to USD 76. These firms cite the robust performance of Corcept's drug Korlym and the growth potential in the patient base as key factors.

The positive outlook is further supported by the progress of Corcept's Phase 3 program for Relacorilant, its next-generation treatment. The company is on track to file for regulatory approval of Relacorilant in the fourth quarter of 2024. In addition, upcoming trials and an upcoming litigation with TEVA are seen as potential catalysts for the company.

Corcept is also expanding into other therapeutic areas, including oncology and metabolic disorders, and is currently conducting trials for various diseases. These recent developments underscore Corcept Therapeutics' strong position and potential for future growth in the biotech sector.

InvestingPro Insights

HC Wainwright's bullish outlook is in line with several key metrics and InvestingPro insights. Corcept Therapeutics' current market capitalization is $4.93 billion, reflecting investor confidence in the company's growth potential. The company's revenue growth of 33.04% in the last twelve months and an impressive 39.15% in the last quarter underpin the analyst's positive view on Korlym's revenue performance.

InvestingPro Tips emphasizes that Corcept has been very profitable over the last twelve months and is expected to remain profitable this year. This profitability is further underlined by the company's strong gross profit margin of 98.49%, which indicates efficient cost management in its core businesses.

The share's recent performance has been remarkable, with a price return of 108.16% over the last six months and a return of 66.74% over the last year. This is in line with InvestingPro's tip that Corcept is trading near its 52-week high and is currently at 97.34% of that peak.

https://www.investing.com/news/company-news/corcept-therapeutics-stock-target-raised-buy-rating-on-cushings-franchise-growth-93CH-3670992

Increase in the healthcare sector

My new investment. $CORT (-6,13 %)

Performance

5years. 227%. 10years 1626%

P/E RATIO

2024: 31,4. 2025: 20,50

Earnings growth

2025: 55,30%. 2026: 50,50%

Earnings per share

2024: 1,12. 2025: 1,84. 2026: 2,75

Free cash flow

2024: 170million. 2025: 258million

EbiT margin

2024: 20%. 2025: 30%. 2026: 40%

Market capitalization: 4.11bn.

Key figures such as margin and free cash flow will increase enormously.

Corcept Therapeutics benefits from higher prevalence of hypercortisolism - Truist sees share price potential of 65%!

The biotech company Corcept Therapeutics (CORT) specializes in cortisol modulation to block the effect of the excess stress hormone cortisol in the body. Excessive production (hypercortisolism) can trigger Cushing's syndrome, which is accompanied by symptoms such as weight gain, high blood pressure or depression. It can also be associated with cancer. Korlym, which has been approved by the FDA since 2012, is a treatment option that once again saw record numbers of new prescriptions from doctors and patients in the last quarter. A marketing authorization application for the more effective Relacorilant is to be submitted in the fourth quarter. CEO Joseph Belanoff emphasized: "Physicians are increasingly aware that hypercortisolism is much more common than previously thought, so they are screening more patients for this disorder."

For example, the CATALYST study recently showed that the prevalence is much higher than previously thought, with around 24% of patients with difficult-to-control type 2 diabetes being diagnosed with hypercortisolism instead of the expected 2.5%. The in-house research team has developed a library of more than 1,000 selective cortisol modulators with different pharmacodynamic properties. Mechanisms of action of Relacorilant for the treatment of prostate cancer and adrenal cancer are also being tested. According to studies, the survival rate of platinum-resistant ovarian cancer, a type of ovarian cancer, has already been doubled from 14% to 29%.

The 2nd quarter recently impressed with an increase in sales of over 39%. The Truist analysts raised the price target from USD 65 to USD 76 (Buy) on September 30 and still see upside potential of around 65%. The experts emphasize that the continued momentum in Korlym's uptake over a decade after its market launch is "impressive and hard to ignore". In the current fiscal year, Corcept aims to grow again by 33 to 39 %. The P/E ratio will fall from 41.6 to 14.2 by 2027. The momentum stock is now generating new buy signals.

https://aktien-mag.de/nachrichten/chart-tweets/corcept-therapeutics-profitiert-von-hoherer-pravalenz-bei-hypercortisolismus-truist-sieht-kurspotenzial-von-65/p-128122